Home » Clinical Trials » Leukemia » NCT04035434
NCT04035434

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

Study Summary

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.

Want to learn more about this trial?

Request More Info

Interventions

CTX110BIOLOGICAL
CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components

Study Locations

FacilityCityStateCountry
Cedars SinaiLos AngelesCaliforniaUnited States
UCSF Medical CenterSan FranciscoCaliforniaUnited States
Mayo ClinicJacksonvilleFloridaUnited States
Emory University Winship Cancer InstituteAtlantaGeorgiaUnited States
University of ChicagoChicagoIllinoisUnited States
University of KansasWestwoodKansasUnited States
Markey Cancer Center, University of KentuckyLexingtonKentuckyUnited States
University of MarylandBaltimoreMarylandUnited States
Beth Israel Deaconess Medical CenterBostonMassachusettsUnited States
University of MinnesotaMinneapolisMinnesotaUnited States
Washington UniversitySt LouisMissouriUnited States
Roswell Park Cancer InsituteBuffaloNew YorkUnited States
Weill Cornell Medical College / New York Presbyterian HospitalNew YorkNew YorkUnited States
Duke UniversityDurhamNorth CarolinaUnited States
Oregon Health and Science UniversityPortlandOregonUnited States
Fox Chase Cancer CenterPhiladelphiaPennsylvaniaUnited States
Sarah Cannon Research InstituteNashvilleTennesseeUnited States
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical CenterDallasTexasUnited States
Texas Transplant InstituteSan AntonioTexasUnited States
Virginia Commonwealth University Massey Cancer CenterRichmondVirginiaUnited States
Swedish Cancer InstituteSeattleWashingtonUnited States
Royal Prince Alfred HospitalSydneyNew South WalesAustralia
Peter MacCallum Cancer CentreMelbourneVictoriaAustralia
Sir Charles Gairdner HospitalNedlandsWestern AustraliaAustralia
Princess Margaret Cancer CentreTorontoOntarioCanada
CHU de LilleLilleFrance
Institut Paoli-CalmettesMarseilleFrance
Hôpital Saint AntoineParisFrance
University of HamburgHamburgGermany
University Hospital WürzburgWürzburgGermany
Clinica Universidad de NavarraPamplonaNavarreSpain
Hospital Clínic de BarcelonaBarcelonaSpain
Hospital Universitario de SalamancaSalamancaSpain

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026